Myomo Inc
AMEX:MYO
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.77
5.63
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Myomo Inc
Capital Expenditures
Myomo Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Myomo Inc
AMEX:MYO
|
Capital Expenditures
-$531.6k
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Capital Expenditures
-$725m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-1%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Capital Expenditures
-$780m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-10%
|
|
|
Stryker Corp
NYSE:SYK
|
Capital Expenditures
-$634m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-11%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Capital Expenditures
-$2.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-67%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-33%
|
|
Myomo Inc
Glance View
Myomo, Inc. is a medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2017-06-12. The firm offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The firm develops and markets the MyoPro product line. The MyoPro is a myoelectric-controlled upper limb brace (orthosis). The orthosis is a rigid brace used for the purpose of supporting a patient’s weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs), in the home and community. The MyoPro can enable individuals to self-initiate and control movements of a partially paralyzed or weakened limb using their own muscle signals. The Company’s products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. The company primarily provides devices directly to patients and bills their insurance companies.
See Also
What is Myomo Inc's Capital Expenditures?
Capital Expenditures
-531.6k
USD
Based on the financial report for Sep 30, 2024, Myomo Inc's Capital Expenditures amounts to -531.6k USD.
What is Myomo Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-62%
Over the last year, the Capital Expenditures growth was -352%. The average annual Capital Expenditures growth rates for Myomo Inc have been -19% over the past three years , -62% over the past five years .
You don't have any saved screeners yet
